|
1 Indications And Usage Rydapt Is A Kinase Inhibitor Indicated For The Treatment Of Adult Patients With: Newly Diagnosed Acute Myeloid Leukemia (Aml) That Is Flt3 Mutation-Positive As Detected By An Fda-Approved Test, In Combination With Standard Cytarabine And Daunorubicin Induction And Cytarabine Consolidation. ( 1.1 ) Limitations Of Use: Rydapt Is Not Indicated As A Single-Agent Induction Therapy For The Treatment Of Patients With Aml. Aggressive Systemic Mastocytosis (Asm), Systemic Mastocytosis With Associated Hematological Neoplasm (Sm-Ahn), Or Mast Cell Leukemia (Mcl). ( 1.2 ) 1.1 Acute Myeloid Leukemia Rydapt Is Indicated, In Combination With Standard Cytarabine And Daunorubicin Induction And Cytarabine Consolidation Chemotherapy, For The Treatment Of Adult Patients With Newly Diagnosed Acute Myeloid Leukemia (Aml) Who Are Flt3 Mutation-Positive, As Detected By A Fda Approved Test [See Dosage And Administration (2.1), Clinical Studies (14.1)]. Limitations Of Use Rydapt Is Not Indicated As A Single-Agent Induction Therapy For The Treatment Of Patients With Aml. 1.2 Systemic Mastocytosis Rydapt Is Indicated For The Treatment Of Adult Patients With Aggressive Systemic Mastocytosis (Asm), Systemic Mastocytosis With Associated Hematological Neoplasm (Sm-Ahn), Or Mast Cell Leukemia (Mcl).
|